Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

ARS Pharmaceuticals, Inc. - Common Stock (NQ:SPRY)

5.950 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 5.950
Bid (Size) 5.800 (100)
Ask (Size) 6.250 (200)
Prev. Close 5.950
Today's Range 5.950 - 5.950
52wk Range 4.910 - 17.54
Shares Outstanding 95,568,307
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRY
From Pomerantz LLP
Via GlobeNewswire
News headline image
Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to Contact the Firm to Learn About Their Legal Rights
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit Retirement

Performance

YTD
-48.2%
-48.2%
1 Month
-23.1%
-23.1%
3 Month
-31.1%
-31.1%
6 Month
-40.0%
-40.0%
1 Year
-63.7%
-63.7%

More News

Read More
News headline image
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
ARS Pharmaceuticals (NASDAQ:SPRY) Reports Revenue Growth in Q1 2026, Net Loss Widens on Commercial Investment ↗
Via Chartmill
News headline image
ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – SPRY
From DJS LAW GROUP
Via Business Wire
News headline image
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
ARS PHARMACEUTICALS LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against ARS Pharmaceuticals and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Rosen Law Firm Urges ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
SPRY DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Shareholder Notice: Robbins LLP Informs Investors of the ARS Pharmaceuticals Inc. Class Action
From Robbins LLP
Via Business Wire
News headline image
ARS Pharmaceuticals Announces Conference Call and Webcast on August 13 Outlining its Updated Strategic Priorities and Reporting Second Quarter 2026 Financial Results
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY
From Pomerantz LLP
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Announces CEO Succession
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
SPRY Investor Alert: Levi & Korsinsky Investigates ARS Pharmaceuticals (SPRY) for Potential Securities Fraud
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY
From Pomerantz LLP
Via GlobeNewswire
News headline image
SPRY Investors Have Opportunity to Join ARS Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Which stocks are moving before the opening bell on Thursday? ↗
Via Chartmill
These stocks are moving in today's after hours session ↗
Via Chartmill
News headline image
ARS Pharmaceuticals Provides Commercial and Financial Updates
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Drew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergies
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharma (SPRY) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
ARS Pharma (SPRY) Q4 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
ARS Pharmaceuticals Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings

Frequently Asked Questions

Is ARS Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, ARS Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does ARS Pharmaceuticals, Inc. - Common Stock trade on?
ARS Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ARS Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for ARS Pharmaceuticals, Inc. - Common Stock is SPRY on the Nasdaq Stock Market
What is the current price of ARS Pharmaceuticals, Inc. - Common Stock?
The current price of ARS Pharmaceuticals, Inc. - Common Stock is 5.950
When was ARS Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of ARS Pharmaceuticals, Inc. - Common Stock was at 08/11/26 04:00 PM ET
What is the market capitalization of ARS Pharmaceuticals, Inc. - Common Stock?
The market capitalization of ARS Pharmaceuticals, Inc. - Common Stock is 568.63M
How many shares of ARS Pharmaceuticals, Inc. - Common Stock are outstanding?
ARS Pharmaceuticals, Inc. - Common Stock has 569M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.